Related Experiment Video
Updated: Jun 27, 2026

Colon Ascendens Stent Peritonitis CASP - a Standardized Model for Polymicrobial Abdominal Sepsis
Published on: December 18, 2010
miR-199a-5p Exacerbated Intestinal Barrier Dysfunction through Inhibiting Surfactant Protein D and Activating NF-κB
Xianjin Du1, Dan Tian1, Jie Wei1
1Department of Emergency, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan, China.
Abstract:
Sepsis is a severe disease, which results from the excessive inflammatory response to the infection. Dysfunction of intestinal barrier is a crucial problem in various pathological conditions. Meanwhile, microRNAs exhibit significant roles in the modulation of many diseases, including sepsis. Multiple investigations indicate that miR-199a-5p participates in different human diseases. Nevertheless, little is known on the roles of miR-199a-5p in sepsis. Herein, we evaluated the mechanism of miR-199a-5p on the intestinal barrier dysfunction in sepsis. Intestinal mucosa permeability indicators including D-lactic acid, DAO, and FD-40 levels were determined, and they were greatly increased in sepsis. Then, we proved that miR-199a-5p was induced in sepsis mice tissues and isolated intestinal epithelial cells. Moreover, miR-199a-5p increased D-lactic acid, DAO, and FD-40 while inhibition of miR-199a-5p exhibited a reversed process. Additionally, we observed that miR-199a-5p affected the oxidative damage and inflammation in the intestine tissues from sepsis mice. The content of MDA was elevated whereas SOD was remarkably repressed in the miR-199a-5p mimic group. IL-6, IL-1β, and TNF-α were induced by miR-199a-5p overexpression while IL-10 was reduced by miR-199a-5p. Subsequently, surfactant protein D (SP-D) was predicted as the target of miR-199a-5p. The activation of NF-κB has been identified in sepsis. Herein, we demonstrated that inhibitor of miR-199a-5p contributed to IEC injury via targeting SP-D and inactivating the NF-κB pathway. These revealed miR-199a-5p exacerbated the intestinal barrier dysfunction via inhibiting SP-D and activating the NF-κB pathway in sepsis.
Insights
MicroRNA-199a-5p worsens sepsis-induced intestinal barrier dysfunction by inhibiting surfactant protein D and activating the NF-κB pathway. Inhibiting miR-199a-5p shows therapeutic potential for sepsis.
Area of Science:
- Biomedical Science
- Molecular Biology
- Pathophysiology
Background:
- Sepsis involves excessive inflammation and intestinal barrier dysfunction.
- MicroRNAs (miRNAs) play roles in disease, but miR-199a-5p's function in sepsis is unclear.
- Intestinal barrier integrity is critical in sepsis progression.
Purpose of the Study:
- To investigate the mechanism of miR-199a-5p in sepsis-induced intestinal barrier dysfunction.
- To determine the role of miR-199a-5p in regulating intestinal permeability, oxidative stress, and inflammation during sepsis.
- To identify the molecular targets and pathways affected by miR-199a-5p in sepsis.
Main Methods:
- Assessed intestinal permeability markers (D-lactic acid, DAO, FD-40) in sepsis models.
- Quantified miR-199a-5p expression in sepsis-induced tissues and cells.
- Measured oxidative stress markers (MDA, SOD) and inflammatory cytokines (IL-6, IL-1β, TNF-α, IL-10).
- Utilized bioinformatics to predict miR-199a-5p targets and validated surfactant protein D (SP-D) and NF-κB pathway involvement.
Main Results:
- miR-199a-5p levels were elevated in sepsis, increasing intestinal permeability and oxidative damage.
- Overexpression of miR-199a-5p promoted inflammation (IL-6, IL-1β, TNF-α) and reduced IL-10.
- miR-199a-5p targeted SP-D, inhibiting its expression and activating the NF-κB pathway, leading to intestinal epithelial cell injury.
Conclusions:
- miR-199a-5p exacerbates intestinal barrier dysfunction in sepsis.
- The mechanism involves inhibiting SP-D and activating the NF-κB pathway.
- Targeting miR-199a-5p may offer a therapeutic strategy for sepsis-related intestinal injury.
More Related Videos
Related Concept Videos
Inflammatory Bowel Disease II: Ulcerative Colitis
Inflammatory Bowel Disease III: Crohn's Disease

